Agenus Poised for Breakthrough with Upcoming Clinical Data
AI Prediction of Agenus Inc. (AGEN)
Agenus Inc. is poised for a significant potential breakthrough with its lead assets botensilimab and balstilimab in the treatment of metastatic colorectal cancer, with upcoming clinical data presentations that could catalyze its stock price.
Agenus Inc., a clinical-stage biotechnology company, focuses on immuno-oncology treatments with its leading candidates botensilimab and balstilimab. These drugs are currently in late-stage clinical trials for metastatic colorectal cancer (mCRC), a market with significant unmet needs. The company is expected to present crucial data at the upcoming AACR 2026 event on April 21, which could substantially impact its valuation and market position. A positive outcome could validate the efficacy of its treatment regimen, potentially leading to accelerated approval and commercialization. This event serves as a critical inflection point for Agenus, offering significant upside potential for investors if the results are favorable.
AGEN Report Information
Prediction Date2026-03-25
Close @ Prediction$3.56
Mkt Cap152m
IPO DateN/a
AI-derived Information
Recent News for AGEN
- Apr 3, 7:30 am — Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026 (Business Wire)
- Apr 1, 7:30 am — Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer (Business Wire)
- Mar 26, 4:52 pm — Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access (Business Wire)
- Mar 17, 4:40 pm — Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer (Business Wire)
- Mar 16, 7:41 pm — Agenus: Q4 Earnings Snapshot (Associated Press Finance)
- Mar 16, 7:30 am — Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized (Business Wire)
- Mar 10, 7:30 am — Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs (Business Wire)
- Mar 4, 4:30 pm — Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update (Business Wire)
- Feb 24, 9:33 am — Agenus (AGEN) Presents New Phase 1b Clinical Data on BOT/BAL Combination for MSS mCRC (Insider Monkey)
- Feb 19, 3:15 pm — Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL (Business Wire)
- Feb 9, 1:00 pm — Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors (Business Wire)
- Jan 28, 8:00 pm — Agenus Webcast: Zydus Manufacturing Deal Closes, France Access Expands, Phase 3 BATMAN Nears Launch (MarketBeat)
NDAPR (News-Driven AI Prediction Revision) events for AGEN
-
Apr 6, 6:59 pmRevision: NO_CHANGE | Price Dir: NONE | Thesis: ACTIVE | Reason: Upcoming AACR presentationRationale: Catalyst progress with AACR presentation still scheduled.
-
Mar 26, 4:57 pmRevision: NO_CHANGE | Price Dir: NONE | Thesis: ACTIVE | Reason:Rationale: Catalyst progress confirmed, no change to prediction or market impact.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest